Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2024 call → NO我们只需要判断管理层是否描述了“同类业务的新订单/合同/项目规模在逐步增大”这一现象。在电话会议中,管理层提到了多个战略举措,但我们需要聚焦于“重复性业务”的规模升级。 检查内容: - 关于CS Neptune(一种高价值流体),管理层提到“discussions with two different super majors, for two different projects in the Gulf of Mexico continue to evolve for projects that are scheduled for the fourth quarter of 2024 or early 2025.” 但这是关于未来项目的讨论,不是已经签署的更大规模订单。 - 关于水处理和回收,管理层提到“we remain in close contact with Eos... fully expect Eos to be up and running their Z3 zinc bromine battery automation line in the second half of this year, which is expected to result material sales of electrolyte from TETRA.” 这是预期未来销售,不是已发生的更大规模。 - 关于溴项目,管理层提到“we hope to publish our Arkansas Bromine Definitive Feasibility Report... with updated financials taking into account the shared CapEx investment and OpEx sharing with our planned Lithium Joint Venture, ExxonMobil.” 这是项目计划,不是已签署的更大订单。 - 关于水处理项目,管理层提到“we're hopeful to have our first commercial desalination for beneficial reuse contract in place that should be operational by the first part of 2025.” 这是第一个合同,不是逐步增大的规模。 没有看到管理层明确说“我们现在的订单规模比过去大”或类似表述。他们提到了一些增长,但都是整体业务增长,没有具体说单个项目/合同的规模在升级。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.